Amy Manley
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Amy Manley has a total of 16 co-authors. Here are the top co-authors by number of shared publications:
Surya Chitra
2 shared publicationsCourtney Kirsch
1 shared publicationDaniel H. Deck
1 shared publication- Diane Anastasiou
Paratek Pharmaceuticals, Inc. , king of Prussia, Pennsylvania
1 shared publication Evan Tzanis
Paratek Pharmaceuticals, Inc., King of Prussia, USA
1 shared publication- Iryna O. Hovbakh
Department of General Practice–Family Medicine, Kharkiv National Medical University, Kharkiv
1 shared publication
Latest Publications
- Open Access
- 21 November 2025
- Published by Elsevier in eClinicalMedicine
- Vol. 90
Omadacycline versus moxifloxacin for community-acquired bacterial pneumonia (OPTIC-2): a phase 3b, randomised, double-blind, multicentre, controlled, noninferiority trial
- 21 November 2025
- Published by Elsevier in eClinicalMedicine
- Vol. 90
Open AccessOmadacycline versus moxifloxacin for community-acquired bacterial pneumonia (OPTIC-2): a phase 3b, randomised, double-blind, multicentre, controlled, noninferiority trial
- Open Access
- 12 November 2020
- Published by Springer Nature in European Journal of Drug Metabolism and Pharmacokinetics
- Vol. 46 (1) , 85-92
The Effect of Verapamil, a P-gp Inhibitor, on the Pharmacokinetics, Safety, and Tolerability of Omadacycline in Healthy Adults: A Phase I, Open-Label, Single-Sequence Study
Background Omadacycline is a semisynthetic aminomethylcycline antibacterial derived from the tetracycline class. It is approved in the USA to treat adults with acute bacterial skin and skin-structure infections and community-acquired bacterial pneumonia. Objectives This phase I, open-label study evaluated the effect of a potential drug–drug interaction of verapamil—a known P-glycoprotein (P-gp) inhibitor—with omadacycline on the pharmacokinetic profile of omadacycline in healthy adults. The safety and tolerability of omadacycline taken alone and in combination with verapamil were also evaluated. Methods A single oral dose of 240 mg verapamil extended release (ER) was given 2 h prior to a single oral dose of 300 mg omadacycline. Results Ten (83.3%) of the 12 participants enrolled in the study completed the study, and all enrolled participants were included in the safety and pharmacokinetic populations. An increase of 14–25% in systemic exposure to omadacycline was seen when administered following a single oral dose of 240 mg verapamil ER compared with omadacycline alone, as measured by the area under the concentration–time curve (AUC) from time 0 to 24 h after dosing (AUC0–24), from time 0 to the last quantifiable concentration (AUC0–t), from time 0 extrapolated to infinity (AUC0–inf), and by maximum (peak) observed plasma concentration (Cmax). Treatment-emergent adverse events were reported by one participant (nausea and headache). Conclusions These findings suggest that, if given with a known P-gp inhibitor, dose adjustment of oral omadacycline is not warranted based on small increases in absorption and systemic exposure. No safety signals were identified.
- 12 November 2020
- Published by Springer Nature in European Journal of Drug Metabolism and Pharmacokinetics
- Vol. 46 (1) , 85-92
Open AccessThe Effect of Verapamil, a P-gp Inhibitor, on the Pharmacokinetics, Safety, and Tolerability of Omadacycline in Healthy Adults: A Phase I, Open-Label, Single-Sequence Study
Background Omadacycline is a semisynthetic aminomethylcycline antibacterial derived from the tetracycline class. It is approved in the USA to treat adults with acute bacterial skin and skin-structure infections and community-acquired bacterial pneumonia. Objectives This phase I, open-label study evaluated the effect of a potential drug–drug interaction of verapamil—a known P-glycoprotein (P-gp) inhibitor—with omadacycline on the pharmacokinetic profile of omadacycline in healthy adults. The safety and tolerability of omadacycline taken alone and in combination with verapamil were also evaluated. Methods A single oral dose of 240 mg verapamil extended release (ER) was given 2 h prior to a single oral dose of 300 mg omadacycline. Results Ten (83.3%) of the 12 participants enrolled in the study completed the study, and all enrolled participants were included in the safety and pharmacokinetic populations. An increase of 14–25% in systemic exposure to omadacycline was seen when administered following a single oral dose of 240 mg verapamil ER compared with omadacycline alone, as measured by the area under the concentration–time curve (AUC) from time 0 to 24 h after dosing (AUC0–24), from time 0 to the last quantifiable concentration (AUC0–t), from time 0 extrapolated to infinity (AUC0–inf), and by maximum (peak) observed plasma concentration (Cmax). Treatment-emergent adverse events were reported by one participant (nausea and headache). Conclusions These findings suggest that, if given with a known P-gp inhibitor, dose adjustment of oral omadacycline is not warranted based on small increases in absorption and systemic exposure. No safety signals were identified.